Zavorno in nadomestno zdravljenje s ščitničnimi hormoni
Suppressive and substitution therapy with thyroid hormones
Ključne besede:
ščitnični hormoni, rakPovzetek
Ni abstrakta.
Abstract (Eng)
A patient with papillary or follicular thyroid carcinoma and unfavorable prognostic factors should have low serum TSH level in order to diminish the risk of recurrence. However, in order to prevent side effects on target organs (heart, bones), the levels of thyroid hormones should be inside the normal reference range. Whenever the thyroid doesn't produce enough hormones in a patient with a benign thyroid disease, the patient should be treated with a hormone replacement therapy. The aim of the substitution therapy is that TSH, free T4 and free T3 are inside the normal reference ranges. Bioequivalence of different generic drugs with thyroxin may differ from 12.5 to 25%. Therefore, if one thyroxine drug is changed with another one, a laboratory test of TSH level has to be performed after six weeks.
Prenosi
Objavljeno
Kako citirati
Številka
Rubrike
Licenca
Revija Onkologija izhaja v skladu s pogoji licence Creative Commons Attribution CC-BY 4.0. Avtorji obdržijo materialne avtorske pravice do svojega dela.
Revija Onkologija je odprtodostopna revija, kar pomeni, da so vsi članki revije brezplačno in prosto dostopni. V skladu z Budimpeško pobudo za prosto dostopnost (BOAI) lahko uporabniki brez predhodne privolitve založnika ali avtorja prebirajo, prenašajo, kopirajo, distribuirajo, tiskajo, iščejo ali ustvarjajo povezave do polnih besedil prispevkov oz. jih uporabljajo v kakršne koli druge zakonite namene, v kolikor ob tem primerno navedejo avtorje in revijo.
